Deals, Development and Manufacturing

The goal of the investment is for the cures to be made available across the globe, including in sub-Saharan Africa’s low-resource communities.

The partners have developed a scalable, cost-effective purification process for adeno-associated viruses.

The therapy received positive results in a randomized, double-blind, placebo-controlled clinical trial in 34 adults with proven celiac disease.

Under the agreement, gene and cell therapy companies can go directly to Aldevron for NTC’s technology without acquiring a license from NTC.

The company will produce the anti-HER3 antibody drug HMBD-001for use within a clinical partnership between Cancer Research UK and Hummingbird Bioscience to test the agent in a Phase I trial.

The transaction is set to be completed in the first quarter of 2020.

Through the agreement, Foamix will have access to $20 million of financing to fund the commercial launches of the topical treatments.

The transaction is anticipated to close by the end of 2019.

A complete understanding of primary packaging physicochemical properties is necessary in the formulation and development of biologics.

Orgenesis has signed a co-development agreement with Accelix to integrate advanced optic technologies, cartridges, and software onto POCare platform.

GammaDelta Therapeutics has unveiled the formation of a new spin-out company, Adaptate Biotherapeutics, aimed at developing antibody-based therapies that modulate gamma delta T-cells.

Enterprise Therapeutics is the recipient of funding worth up to £5.7 million (US $7 million) from the Cystic Fibrosis Foundation.

The long-term agreement gives CombiGene the authority to manufacture and commercialize the drug if it is approved after clinical studies.

The transaction gives Alexion access to Achillion’s portfolio of oral small-molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases.

Lonza, through its Ibex Solutions, will now cover preclinical and clinical development and manufacturing for a significant portion of Genmab’s pipeline.

The Italy-based pharmaceutical glass and plastic packaging manufacturer, announced it will be showcasing its prototypes for usability, sustainability, connectivity, and traceability.

As the world awaits the outcome of Brexit, a presentation taking place at CPhI Worldwide in Frankfurt, Germany will delve deeper into the implications of each potential scenario on the pharma industry.

The companies will collaborate to identify and develop in-vivo genome editing therapeutic candidates for genetic diseases, including hemophilia.

The collaboration aims to reduce “vein-to-vein” time for patients and to optimize manufacturing and supply operations.

The new location will handle logistics, development, data, service support, FAT, and project management.

MilliporeSigma will now be the first company to make acoustic technology available for cell therapy manufacturing.

The new device protects children from accidentally taking painkillers, antidepressants, or medical cannabis with a new opening mechanism.

The acquisition comes after Bormioli became an independent company owned by Triton Investment Fund in December 2017.

The collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs neurodegenerative diseases.

Under a collaboration potentially worth more than $1.5 billion, the companies aim to develop the antisense therapy to treat patients with certain cardiovascular and metabolic diseases.

When the injector design is finalized, Stevanato Group will produce it at one of its manufacturing facilities using extensive tooling, molding, and assembly expertise.

GSK invested $139 million to its Rockville, MD site to support demand for Benlysta.

The companies are working together with Japanese clients to outline projects from early clinical stage up to commercial launch.

The new joint venture, named Oerth Bio, will use Arvinas’ Protac technology to develop innovative new agricultural products. As part of its collaboration with Arvinas, Bayer is also using this technology to develop human therapeutics.

Manufacturing of the cell line will take place at Lonza’s GMP facility in Geleen, Netherlands.